Adequate risk assessment and management are crucial in preventing cardiovascular disease. A recent study examined the correlation between common measures of cholesterol concentration versus the number of apolipoprotein B (apo-B)-containing lipoproteins. In other words, should clinicians use different biomarkers for cardiovascular risk assessment? Cardiology Pharmacist, Lindsay Davis, joins Geoff Wall in this discussion.
The GameChanger
Evidence is emerging to suggest apo-B is a more accurate biomarker of MI risk. While not routinely evaluated, apo-B is a GameChanger in that it can be helpful in determining cardiovascular risk in patients with borderline risk factors.
Show Segments
00:00 – Introductions
03:22 – Apolipoprotein B (apo-B)
05:22 – Biomarkers for Cardiovascular Disease
12:58 – The GameChanger
20:37 – Connecting to Practice
28:49 – Closing Remarks
Host
Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Guest:
Lindsay Davis, PharmD, BCPS, BCCP, TTS, ASH-CHC
Professor, Midwestern University
Lindsay Davis has no relevant financial relationships to discuss.
References and resources:
Redeem your CPE or CME credit
Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Continuing Education Information:
Learning Objectives:
1. Describe the role of apolipoprotein B in cardiovascular management
2. Identify patients that may benefit from apolipoprotein B testing
All relevant financial relationships have been mitigated.
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-232-H01-P
Initial release date: 06/20/22
Expiration date: 06/20/2023
Additional CPE & CME details can be found here